Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2012 2
2013 2
2014 1
2017 1
2018 2
2019 2
2020 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Somatostatin Receptor-negative and Fluorodeoxyglucose-positron Emission Tomography-positive Lung Neuroendocrine Tumor G1 Exhibiting Cyclic Cushing's Syndrome.
Nomura C, Nakano Y, Tanaka T, Shima KR, Kometani M, Kanamori T, Ikeda H, Takeshita Y, Yoneda T, Takamura T. Nomura C, et al. Among authors: shima kr. Intern Med. 2022 Dec 15;61(24):3693-3698. doi: 10.2169/internalmedicine.9238-21. Epub 2022 May 31. Intern Med. 2022. PMID: 35650126 Free PMC article.
A novel PHEX mutation associated with vitamin D-resistant rickets.
Sako S, Niida Y, Shima KR, Takeshita Y, Ishii KA, Takamura T. Sako S, et al. Among authors: shima kr. Hum Genome Var. 2019 Feb 14;6:9. doi: 10.1038/s41439-019-0040-3. eCollection 2019. Hum Genome Var. 2019. PMID: 30792871 Free PMC article.
Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
Takeshita Y, Kita Y, Tanaka T, Goto H, Nakano Y, Teramura C, Enyama Y, Takamura T; Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Group. Takeshita Y, et al. J Diabetes Investig. 2022 Jun;13(6):965-974. doi: 10.1111/jdi.13749. Epub 2022 Feb 8. J Diabetes Investig. 2022. PMID: 35034428 Free PMC article. Clinical Trial.
Mediastinal thyroid goiter with no accumulation on scintigraphy.
Kahara T, Ichikawa T, Taniguchi H, Shinnou H, Sumiya H, Uchiyama A, Ishizawa S, Shima KR, Usuda R. Kahara T, et al. Among authors: shima kr. Intern Med. 2013;52(18):2159. doi: 10.2169/internalmedicine.52.0710. Intern Med. 2013. PMID: 24042534 Free article. No abstract available.
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S. Otoda T, et al. Among authors: shima kr. Diabetes. 2013 Mar;62(3):811-24. doi: 10.2337/db11-1652. Epub 2012 Dec 3. Diabetes. 2013. PMID: 23209186 Free PMC article.
Autoimmune polyglandular syndrome type 3 with anorexia.
Kahara T, Wakakuri H, Takatsuji J, Motoo I, Shima KR, Ishikura K, Usuda R, Noda Y. Kahara T, et al. Among authors: shima kr. Case Rep Endocrinol. 2012;2012:657156. doi: 10.1155/2012/657156. Epub 2012 Dec 13. Case Rep Endocrinol. 2012. PMID: 23304573 Free PMC article.
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Yoshida H, Sato Y, Ikehara Y, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Among authors: shima kr. Diabetes Care. 2019 Oct;42(10):e159-e161. doi: 10.2337/dc19-1177. Epub 2019 Sep 18. Diabetes Care. 2019. PMID: 31533913 No abstract available.
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial.
Tanaka A, Shimabukuro M, Teragawa H, Yoshida H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Hypertens Res. 2024 May 24. doi: 10.1038/s41440-024-01725-4. Online ahead of print. Hypertens Res. 2024. PMID: 38789538
15 results